China Medical Device Regulatory Outsourcing

Mandatory in-country testing, the necessity for local legal representation, and the frequent updates to regulations and technical standards contribute to a highly intricate approval process. These requirements differ significantly from those in the U.S. or EU, making local expertise and assistance not just beneficial, but essential.

For medical device companies, this complexity emphasizes three critical priorities: accelerating time to market, ensuring full regulatory compliance, and controlling operational costs. Achieving all three internally is challenging, especially without a dedicated team on the ground in China. This is why outsourcing regulatory affairs to a specialist provider offers a strategic advantage.

Cisema assists international medical device companies with comprehensive regulatory affairs and compliance services specifically tailored to China. We help you register, launch, and maintain your products in full compliance with NMPA requirements, without the need to develop internal capabilities in China.

We function as your external regulatory department, managing every step from marketing authorizations to PMS. This allows you to stay compliant, competitive, and focused on your core business.

GMP Medical Devices
Outsourcing service

Benefits of Regulatory Affairs Outsourcing Services for China

Local Expertise with Global Integration

Cisema experts will guide you at every stage of product development, ensuring compliance, strategic alignment and a successful market entry. We facilitate interactions with regulatory agencies to streamline the approval process.  

Accelerated Access

By outsourcing regulatory tasks, companies can expedite approvals, seizing commercial opportunities more quickly and responding swiftly to demand.

Efficient

Eliminating the need for internal teams to manage complex regulations reduces overhead and enhances financial efficiency.

Concentration on Core Strengths

By delegating regulatory responsibilities, your internal teams can focus on innovation, production, and business growth, thereby boosting productivity.

Access to Specialized Knowledge

Partnering with an experienced regulatory outsourcing firm like Cisema grants you access to advanced regulatory strategies and technical expertise for efficient authorizations.

Enhanced Compliance & Risk Management

We assist in establishing robust quality systems, maintaining precise documentation, conducting audits, and ensuring adherence to NMPA standards — minimizing the risk of non-compliance.

Independent & Confidential Service

We operate solely on your behalf. As we are not a distributor, there is no conflict of interest, ensuring transparency and trust.

Our Regulatory Affairs Outsourcing Services

Our global presence, including offices in Europe, North America and Asia, allows us to provide a wide range of outsourcing services to medical device companies internationally. We understand the importance of regulatory compliance and quality management systems (QMS) for companies.

NMPA Approvals

Class I, II, and III medical devices
Local type testing, clinical evaluation, and dossier submission
Fast-track and innovative device pathways

Legal Agent & In-Country Representative

Act as your local agent with the NMPA
Maintain product licenses and regulatory compliance
Liaise with Chinese authorities on your behalf

Post-Market Surveillance

Adverse event reporting assistance
Change notifications and license renewals
UDI and tracking system support

Quality Management & Compliance

Compliance with Chinese GMP
Internal audits and documentation support
Risk management planning and implementation

Labeling & Packaging Compliance

Chinese Label and IFU review
UDI and barcode checks
Language and format verification

Regulatory Documentation & Control

Document control and quality system maintenance
Accurate, up-to-date documentation aligned with NMPA expectations

Training & Consultancy

Risk management and quality system training
Preparation for on-site inspections and supplier audits

Useful Articles

View More

Digital Medical Device Clinical Trials in South Korea: Understanding the MFDS Framework

Understand MFDS clinical trial requirements for digital medical devices, including real-world evidence, data-based studies, and software validation expectations.

June 2, 2026
Digital Medical Device Clinical Trials in South Korea: Understanding the MFDS Framework

Cisema Expands into South Korea

Supporting foreign manufacturers entering South Korea with regulatory services for medical devices, IVDs, and quasi-drugs.

June 1, 2026
Cisema Expands into South Korea
Seoul skyline in the early evening

Indonesia Halal Requirements for Medical Devices: What Manufacturers and Importers Need to Know

Learn which products are covered by Indonesia's halal framework, the labeling and manufacturing obligations, and phased compliance timelines.

May 20, 2026
Indonesia Halal Requirements for Medical Devices: What Manufacturers and Importers Need to Know
A healthcare worker in a white coat checks a seated patient’s blood pressure while another medical staff member in green scrubs stands nearby holding a clipboard in a bright clinic setting.

Medical Device Market Access for Thailand, Indonesia, and the Philippines

Cisema offers regulatory insight and market access strategy for medical devices in Thailand, Indonesia, and the Philippines.

May 15, 2026
Medical Device Market Access for Thailand, Indonesia, and the Philippines
Medical Device Market Access for Thailand, Indonesia, and the Philippines

Medical Device Registration in Indonesia: A Practical Guide for Foreign Manufacturers

Learn how to register medical devices in Indonesia, including Authorized Representative rules, classification, dossiers, timelines, and fees.

May 15, 2026
Medical Device Registration in Indonesia: A Practical Guide for Foreign Manufacturers
Three masked surgical staff in green operating room attire stand with folded arms beside a patient lying on an operating table, with medical monitors and X-ray images displayed in a dimly lit operating room.”

Entering China’s Intraocular Lens (IOL) Market: NMPA Registration Requirements for Foreign Manufacturers

Understand the pathway for intraocular lens (IOL) registration in China, including NMPA requirements and key compliance steps.

May 14, 2026
Entering China’s Intraocular Lens (IOL) Market: NMPA Registration Requirements for Foreign Manufacturers
A close-up of an eye with a transparent intraocular lens held by surgical tweezers positioned in front of the pupil, illustrating ophthalmic medical device use. The visual supports themes of regulatory compliance, product registration, and market access
Previous
Previous

Explore Related Services

Whether you’re just starting out or are a blue-chip, access our wide range of services and 
outsourcing solutions to help your business thrive.

China Medical Device Approvals

We guide you through every step of the China medical device registration and filing process. We take care of compliance with NMPA requirements, advising you on the optimal China entry pathway, and helping you through the whole process.

Learn more

NMPA Legal Agent

We are your authorized representative in China, and fulfill your registrations and filings as well as ensuring compliance with quality and PMS requirements.

Learn more

China Clinical Trials

You may be required to provide supplementary clinical data on Chinese patients or conduct a full clinical trial in China.Our clinical research team will advise you, prepare the study protocol and assist setting up the clinical trial in China.

Learn more

NMPA Type Testing

Our on-site test engineers coordinate and supervise type tests of your medical devices in NMPA-accredited laboratories.

Learn more

Drug Device Combination Products

We assist with the classification, authorization, and compliance of combination products in China, whether drug or device led.

Learn more

China Medical Device Quality Compliance

We help you achieve and ensure ongoing compliance with Chinese requirements.Our experts prepare and assist you for official NMPA inspections.

Learn more

Medical Device PMS & Vigilance

The NMPA is placing greater focus on PMS such as more in-China sampling inspections and regular standard changes.Our specialist PMS team means you stay up to date with the many aspects of compliance.

Learn more

NMPA Clinical Evaluation Report

Clinical Evaluation Reports can avoid the need for a China clinical trial in some instances. Our experts can advise and prepare NMPA compliant CERs.

Learn more

Latest Insights

View More

MFDS Issues 2025 Korea Medical Device Regulatory Update Report

Summary of 2025 MFDS trends covering medical device approvals, import dynamics, and the shift toward AI and software-based regulation.

June 2, 2026
MFDS Issues 2025 Korea Medical Device Regulatory Update Report

China Proposes Sweeping New Rules for Drugs, Medical Devices, and Special Foods Advertising

China’s SAMR has released draft advertising review measures that would increase oversight of livestreaming and digital marketing while streamlining certain compliance requirements for regulated products.

June 1, 2026
China Proposes Sweeping New Rules for Drugs, Medical Devices, and Special Foods Advertising

Hong Kong Expands Medical Device Listing Scope for Injectable Dermal Fillers

The updated GN-00 guidance reduces classification uncertainty and creates clearer MDACS pathways for injectable dermal fillers in Hong Kong.

May 29, 2026
Hong Kong Expands Medical Device Listing Scope for Injectable Dermal Fillers
Stock photo of a Chinese woman seated in a modern medical aesthetics clinic just seconds before receiving dermal filler treatment

Malaysia MDA Updates Medical Device Definitions, Special Access, & Legacy Device Rules 

Malaysia’s MDA has issued major updates affecting medical device classification, special access exemptions, and management of obsolete and discontinued devices under the Medical Device Act 2012

May 27, 2026
Malaysia MDA Updates Medical Device Definitions, Special Access, & Legacy Device Rules 
Ultra-photorealistic stock photo of a modern patient monitoring device in active clinical use inside a contemporary Malaysian hospital room.

China Launches Trial Medical Device Vigilance Framework Across 17 Pilot Regions

New measures define vigilance management, inspections, PSURs, trend reporting, and reporting requirements in 17 pilot regions

May 20, 2026
China Launches Trial Medical Device Vigilance Framework Across 17 Pilot Regions

China Launches National AI Roadmap for Pharmaceuticals, Medical Devices, & Cosmetics Supervision

China’s NMPA released a AI roadmap for smarter supervision across drugs, medical devices, and cosmetics regulation, covering AI-supported review, inspections, traceability, risk monitoring, and digital governance through 2035.

May 15, 2026
China Launches National AI Roadmap for Pharmaceuticals, Medical Devices, & Cosmetics Supervision
A business professional sits at a conference table using a laptop displaying a glowing digital brain graphic with the text “AI.” The setting appears to be a modern office with large windows and blurred city buildings in the background.
Previous
Previous

A Reliable Partner from Start to Finish

With over 20 years of experience and a proven track record, Cisema is trusted by startups and global medtech leaders alike to manage China regulatory affairs with efficiency and precision. Contact us today to discuss how we can support your China strategy.

Request Proposal